Blood cancers

Podcast: Where does carfilzomib fit in the R/R multiple myeloma setting?

Sponsored by Amgen Australia Pty Ltd

The treatment landscape for relapsed, refractory multiple myeloma has been constantly evolving with new treatments and trials keeping everyone on their toes. Following the Amgen Multiple Myeloma Webinar Series we speak to Dr Jesús San Miguel and Dr Paula Rodriguez from the University of Pamplona, Spain about where carfilzomib fits in the current treatment paradigm. ...

Already a member?

Login to keep reading.

© 2021 the limbic